Trial Profile
Tau Positron Emission Tomography (PET) Imaging in the Northern Manhattan Study of Metabolism and Mind (NOMEM) With 18F-MK6240.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Florquinitau F18 (Primary)
- Indications Neurodegenerative disorders
- Focus Diagnostic use
- Acronyms NOMEM-Tau
- 01 Mar 2024 Planned number of patients changed from 500 to 600.
- 01 Mar 2024 Planned End Date changed from 30 Jun 2023 to 1 Jun 2026.
- 01 Mar 2024 Planned primary completion date changed from 30 Jun 2023 to 1 Jun 2026.